GLP-1 agonists, dual/triple receptor drugs, and metabolic peptides for weight management
9 PEPTIDES IN THIS CATEGORY
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is a modified human GLP-1 analog with a fatty acid side chain enabli…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…
MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial ge…
Mazdutide (IBI362/OXM3) is a GLP-1/glucagon dual receptor agonist developed by Innovent Biologics (China), based on an o…
Survodutide (BI 456906) is a GLP-1/glucagon dual receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharm…
5-amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme highly overexpressed in…
Retatrutide (LY3437943) is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously…